Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The collaboration will center on expanding access to Eastman’s Esmeri technology
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The new functionality complements Parse’s existing Evercode immune products
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Subscribe To Our Newsletter & Stay Updated
